Skip to main content
Top
Published in: Journal of Translational Medicine 1/2008

Open Access 01-12-2008 | Research

Exosomes as a tumor immune escape mechanism: possible therapeutic implications

Authors: Thomas E Ichim, Zhaohui Zhong, Shalesh Kaushal, Xiufen Zheng, Xiubao Ren, Xishan Hao, James A Joyce, Harold H Hanley, Neil H Riordan, James Koropatnick, Vladimir Bogin, Boris R Minev, Wei-Ping Min, Richard H Tullis

Published in: Journal of Translational Medicine | Issue 1/2008

Login to get access

Abstract

Advances in cancer therapy have been substantial in terms of molecular understanding of disease mechanisms, however these advances have not translated into increased survival in the majority of cancer types. One unsolved problem in current cancer therapeutics is the substantial immune suppression seen in patients. Conventionally, investigations in this area have focused on antigen-nonspecific immune suppressive molecules such as cytokines and T cell apoptosis inducing molecules such as Fas ligand. More recently, studies have demonstrated nanovesicle particles termed exosomes are involved not only in stimulation but also inhibition of immunity in physiological conditions. Interestingly, exosomes secreted by cancer cells have been demonstrated to express tumor antigens, as well as immune suppressive molecules such as PD-1L and FasL. Concentrations of exosomes from plasma of cancer patients have been associated with spontaneous T cell apoptosis, which is associated in some situations with shortened survival. In this paper we place the "exosome-immune suppression" concept in perspective of other tumor immune evasion mechanisms. We conclude by discussing a novel therapeutic approach to cancer immune suppression by extracorporeal removal of exosomes using hollow fiber filtration technology
Literature
2.
4.
go back to reference McCarthy EF: The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J. 2006, 26: 154-158.PubMedCentralPubMed McCarthy EF: The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J. 2006, 26: 154-158.PubMedCentralPubMed
5.
go back to reference Seow SW, Rahmat JN, Mohamed AA, Mahendran R, Lee YK, Bay BH: Lactobacillus species is more cytotoxic to human bladder cancer cells than Mycobacterium Bovis (bacillus Calmette-Guerin). J Urol. 2002, 168: 2236-2239.CrossRefPubMed Seow SW, Rahmat JN, Mohamed AA, Mahendran R, Lee YK, Bay BH: Lactobacillus species is more cytotoxic to human bladder cancer cells than Mycobacterium Bovis (bacillus Calmette-Guerin). J Urol. 2002, 168: 2236-2239.CrossRefPubMed
6.
go back to reference Yoo YC, Hata K, Lee KB, Azuma I: Inhibitory effect of BCG cell-wall skeletons (BCG-CWS) emulsified in squalane on tumor growth and metastasis in mice. Arch Pharm Res. 2002, 25: 522-527.CrossRefPubMed Yoo YC, Hata K, Lee KB, Azuma I: Inhibitory effect of BCG cell-wall skeletons (BCG-CWS) emulsified in squalane on tumor growth and metastasis in mice. Arch Pharm Res. 2002, 25: 522-527.CrossRefPubMed
7.
go back to reference Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL: Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol. 1986, 136: 2348-2357.PubMed Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL: Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol. 1986, 136: 2348-2357.PubMed
8.
go back to reference Coffman RL: Origins of the T(H)1-T(H)2 model: a personal perspective. Nat Immunol. 2006, 7: 539-541.CrossRefPubMed Coffman RL: Origins of the T(H)1-T(H)2 model: a personal perspective. Nat Immunol. 2006, 7: 539-541.CrossRefPubMed
9.
go back to reference Wolchok JD, Vilcek J: Reassessing the usual suspects causing a commotion in the blood (and vessels?). Cancer Biol Ther. 2004, 3: 124-125.CrossRefPubMed Wolchok JD, Vilcek J: Reassessing the usual suspects causing a commotion in the blood (and vessels?). Cancer Biol Ther. 2004, 3: 124-125.CrossRefPubMed
10.
go back to reference Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B: An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA. 1975, 72: 3666-3670.PubMedCentralCrossRefPubMed Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B: An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA. 1975, 72: 3666-3670.PubMedCentralCrossRefPubMed
11.
go back to reference Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH: A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell. 2000, 100: 655-669.CrossRefPubMed Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH: A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell. 2000, 100: 655-669.CrossRefPubMed
12.
go back to reference Murphy KM, Ouyang W, Szabo SJ, Jacobson NG, Guler ML, Gorham JD, Gubler U, Murphy TL: T helper differentiation proceeds through Stat1-dependent, Stat4-dependent and Stat4-independent phases. Curr Top Microbiol Immunol. 1999, 238: 13-26.PubMed Murphy KM, Ouyang W, Szabo SJ, Jacobson NG, Guler ML, Gorham JD, Gubler U, Murphy TL: T helper differentiation proceeds through Stat1-dependent, Stat4-dependent and Stat4-independent phases. Curr Top Microbiol Immunol. 1999, 238: 13-26.PubMed
13.
go back to reference Zhu J, Yamane H, Cote-Sierra J, Guo L, Paul WE: GATA-3 promotes Th2 responses through three different mechanisms: induction of Th2 cytokine production, selective growth of Th2 cells and inhibition of Th1 cell-specific factors. Cell Res. 2006, 16: 3-10.CrossRefPubMed Zhu J, Yamane H, Cote-Sierra J, Guo L, Paul WE: GATA-3 promotes Th2 responses through three different mechanisms: induction of Th2 cytokine production, selective growth of Th2 cells and inhibition of Th1 cell-specific factors. Cell Res. 2006, 16: 3-10.CrossRefPubMed
14.
go back to reference Curiel RE, Lahesmaa R, Subleski J, Cippitelli M, Kirken RA, Young HA, Ghosh P: Identification of a Stat-6-responsive element in the promoter of the human interleukin-4 gene. Eur J Immunol. 1997, 27: 1982-1987.CrossRefPubMed Curiel RE, Lahesmaa R, Subleski J, Cippitelli M, Kirken RA, Young HA, Ghosh P: Identification of a Stat-6-responsive element in the promoter of the human interleukin-4 gene. Eur J Immunol. 1997, 27: 1982-1987.CrossRefPubMed
15.
go back to reference Lederer JA, Perez VL, DesRoches L, Kim SM, Abbas AK, Lichtman AH: Cytokine transcriptional events during helper T cell subset differentiation. J Exp Med. 1996, 184: 397-406.CrossRefPubMed Lederer JA, Perez VL, DesRoches L, Kim SM, Abbas AK, Lichtman AH: Cytokine transcriptional events during helper T cell subset differentiation. J Exp Med. 1996, 184: 397-406.CrossRefPubMed
16.
go back to reference Kacha AK, Fallarino F, Markiewicz MA, Gajewski TF: Cutting edge: spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient mice. J Immunol. 2000, 165: 6024-6028.CrossRefPubMed Kacha AK, Fallarino F, Markiewicz MA, Gajewski TF: Cutting edge: spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient mice. J Immunol. 2000, 165: 6024-6028.CrossRefPubMed
17.
go back to reference Ostrand-Rosenberg S, Grusby MJ, Clements VK: Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma. J Immunol. 2000, 165: 6015-6019.CrossRefPubMed Ostrand-Rosenberg S, Grusby MJ, Clements VK: Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma. J Immunol. 2000, 165: 6015-6019.CrossRefPubMed
18.
go back to reference Ostrand-Rosenberg S, Clements VK, Terabe M, Park JM, Berzofsky JA, Dissanayake SK: Resistance to metastatic disease in STAT6-deficient mice requires hemopoietic and nonhemopoietic cells and is IFN-gamma dependent. J Immunol. 2002, 169: 5796-5804.CrossRefPubMed Ostrand-Rosenberg S, Clements VK, Terabe M, Park JM, Berzofsky JA, Dissanayake SK: Resistance to metastatic disease in STAT6-deficient mice requires hemopoietic and nonhemopoietic cells and is IFN-gamma dependent. J Immunol. 2002, 169: 5796-5804.CrossRefPubMed
19.
go back to reference Zhang SS, Welte T, Fu XY: Dysfunction of Stat4 leads to accelerated incidence of chemical-induced thymic lymphomas in mice. Exp Mol Pathol. 2001, 70: 231-238.CrossRefPubMed Zhang SS, Welte T, Fu XY: Dysfunction of Stat4 leads to accelerated incidence of chemical-induced thymic lymphomas in mice. Exp Mol Pathol. 2001, 70: 231-238.CrossRefPubMed
20.
go back to reference Kalinski P, Giermasz A, Nakamura Y, Basse P, Storkus WJ, Kirkwood JM, Mailliard RB: Helper role of NK cells during the induction of anticancer responses by dendritic cells. Mol Immunol. 2005, 42: 535-539.CrossRefPubMed Kalinski P, Giermasz A, Nakamura Y, Basse P, Storkus WJ, Kirkwood JM, Mailliard RB: Helper role of NK cells during the induction of anticancer responses by dendritic cells. Mol Immunol. 2005, 42: 535-539.CrossRefPubMed
21.
go back to reference Kobayashi N: Malignant neoplasms in registered cases of primary immunodeficiency syndrome. Jpn J Clin Oncol. 1985, 15 (Suppl 1): 307-312.PubMed Kobayashi N: Malignant neoplasms in registered cases of primary immunodeficiency syndrome. Jpn J Clin Oncol. 1985, 15 (Suppl 1): 307-312.PubMed
22.
go back to reference Nakamura E, Megumi Y, Kobayashi T, Kamoto T, Ishitoya S, Terachi T, Tachibana M, Matsushiro H, Habuchi T, Kakehi Y, Ogawa O: Genetic polymorphisms of the interleukin-4 receptor alpha gene are associated with an increasing risk and a poor prognosis of sporadic renal cell carcinoma in a Japanese population. Clin Cancer Res. 2002, 8: 2620-2625.PubMed Nakamura E, Megumi Y, Kobayashi T, Kamoto T, Ishitoya S, Terachi T, Tachibana M, Matsushiro H, Habuchi T, Kakehi Y, Ogawa O: Genetic polymorphisms of the interleukin-4 receptor alpha gene are associated with an increasing risk and a poor prognosis of sporadic renal cell carcinoma in a Japanese population. Clin Cancer Res. 2002, 8: 2620-2625.PubMed
23.
go back to reference Amirzargar A, Lessanpezeshki M, Fathi A, Amirzargar M, Khosravi F, Ansaripour B, Nikbin B: TH1/TH2 cytokine analysis in Iranian renal transplant recipients. Transplant Proc. 2005, 37: 2985-2987.CrossRefPubMed Amirzargar A, Lessanpezeshki M, Fathi A, Amirzargar M, Khosravi F, Ansaripour B, Nikbin B: TH1/TH2 cytokine analysis in Iranian renal transplant recipients. Transplant Proc. 2005, 37: 2985-2987.CrossRefPubMed
24.
go back to reference Daniel V, Naujokat C, Sadeghi M, Wiesel M, Hergesell O, Opelz G: Association of circulating interleukin (IL)-12- and IL-10-producing dendritic cells with time posttransplant, dose of immunosuppression, and plasma cytokines in renal-transplant recipients. Transplantation. 2005, 79: 1498-1506.CrossRefPubMed Daniel V, Naujokat C, Sadeghi M, Wiesel M, Hergesell O, Opelz G: Association of circulating interleukin (IL)-12- and IL-10-producing dendritic cells with time posttransplant, dose of immunosuppression, and plasma cytokines in renal-transplant recipients. Transplantation. 2005, 79: 1498-1506.CrossRefPubMed
25.
go back to reference Kim WU, Cho ML, Kim SI, Yoo WH, Lee SS, Joo YS, Min JK, Hong YS, Lee SH, Park SH: Divergent effect of cyclosporine on Th1/Th2 type cytokines in patients with severe, refractory rheumatoid arthritis. J Rheumatol. 2000, 27: 324-331.PubMed Kim WU, Cho ML, Kim SI, Yoo WH, Lee SS, Joo YS, Min JK, Hong YS, Lee SH, Park SH: Divergent effect of cyclosporine on Th1/Th2 type cytokines in patients with severe, refractory rheumatoid arthritis. J Rheumatol. 2000, 27: 324-331.PubMed
26.
go back to reference Gerlini G, Romagnoli P, Pimpinelli N: Skin cancer and immunosuppression. Crit Rev Oncol Hematol. 2005, 56: 127-136.CrossRefPubMed Gerlini G, Romagnoli P, Pimpinelli N: Skin cancer and immunosuppression. Crit Rev Oncol Hematol. 2005, 56: 127-136.CrossRefPubMed
27.
go back to reference Pluygers E, Sadowska A, Chyczewski L, Niklinski J, Niklinska W, Chyczewska E: The impact of immune responses on lung cancer and the development of new treatment modalities. Lung Cancer. 2001, 34 (Suppl 2): S71-77.CrossRefPubMed Pluygers E, Sadowska A, Chyczewski L, Niklinski J, Niklinska W, Chyczewska E: The impact of immune responses on lung cancer and the development of new treatment modalities. Lung Cancer. 2001, 34 (Suppl 2): S71-77.CrossRefPubMed
28.
go back to reference Birkeland SA, Storm HH, Lamm LU, Barlow L, Blohme I, Forsberg B, Eklund B, Fjeldborg O, Friedberg M, Frodin L: Cancer risk after renal transplantation in the Nordic countries, 1964–1986. Int J Cancer. 1995, 60: 183-189.CrossRefPubMed Birkeland SA, Storm HH, Lamm LU, Barlow L, Blohme I, Forsberg B, Eklund B, Fjeldborg O, Friedberg M, Frodin L: Cancer risk after renal transplantation in the Nordic countries, 1964–1986. Int J Cancer. 1995, 60: 183-189.CrossRefPubMed
29.
go back to reference Khauli RB: Genitourinary malignancies in organ transplant recipients. Semin Urol. 1994, 12: 224-232.PubMed Khauli RB: Genitourinary malignancies in organ transplant recipients. Semin Urol. 1994, 12: 224-232.PubMed
30.
go back to reference Penn I: Depressed immunity and the development of cancer. Cancer Detect Prev. 1994, 18: 241-252.PubMed Penn I: Depressed immunity and the development of cancer. Cancer Detect Prev. 1994, 18: 241-252.PubMed
31.
go back to reference Penn I: Occurrence of cancers in immunosuppressed organ transplant recipients. Clin Transpl. 1994, 99-109. Penn I: Occurrence of cancers in immunosuppressed organ transplant recipients. Clin Transpl. 1994, 99-109.
32.
go back to reference Grulich AE, Wan X, Law MG, Coates M, Kaldor JM: Risk of cancer in people with AIDS. Aids. 1999, 13: 839-843.CrossRefPubMed Grulich AE, Wan X, Law MG, Coates M, Kaldor JM: Risk of cancer in people with AIDS. Aids. 1999, 13: 839-843.CrossRefPubMed
33.
go back to reference Marchand M, van Baren N, Weynants P, Brichard V, Dreno B, Tessier MH, Rankin E, Parmiani G, Arienti F, Humblet Y: Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer. 1999, 80: 219-230.CrossRefPubMed Marchand M, van Baren N, Weynants P, Brichard V, Dreno B, Tessier MH, Rankin E, Parmiani G, Arienti F, Humblet Y: Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer. 1999, 80: 219-230.CrossRefPubMed
34.
35.
go back to reference Wang HH, Mao CY, Teng LS, Cao J: Recent advances in heat shock protein-based cancer vaccines. Hepatobiliary Pancreat Dis Int. 2006, 5: 22-27.PubMed Wang HH, Mao CY, Teng LS, Cao J: Recent advances in heat shock protein-based cancer vaccines. Hepatobiliary Pancreat Dis Int. 2006, 5: 22-27.PubMed
36.
go back to reference Facciponte JG, MacDonald IJ, Wang XY, Kim H, Manjili MH, Subjeck JR: Heat shock proteins and scavenger receptors: role in adaptive immune responses. Immunol Invest. 2005, 34: 325-342.CrossRefPubMed Facciponte JG, MacDonald IJ, Wang XY, Kim H, Manjili MH, Subjeck JR: Heat shock proteins and scavenger receptors: role in adaptive immune responses. Immunol Invest. 2005, 34: 325-342.CrossRefPubMed
37.
go back to reference Garcia-Hernandez E, Gonzalez-Sanchez JL, Andrade-Manzano A, Contreras ML, Padilla S, Guzman CC, Jimenez R, Reyes L, Morosoli G, Verde ML, Rosales R: Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. Cancer Gene Ther. 2006, 13: 592-597.CrossRefPubMed Garcia-Hernandez E, Gonzalez-Sanchez JL, Andrade-Manzano A, Contreras ML, Padilla S, Guzman CC, Jimenez R, Reyes L, Morosoli G, Verde ML, Rosales R: Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. Cancer Gene Ther. 2006, 13: 592-597.CrossRefPubMed
38.
go back to reference Garnett CT, Greiner JW, Tsang KY, Kudo-Saito C, Grosenbach DW, Chakraborty M, Gulley JL, Arlen PM, Schlom J, Hodge JW: TRICOM vector based cancer vaccines. Curr Pharm Des. 2006, 12: 351-361.CrossRefPubMed Garnett CT, Greiner JW, Tsang KY, Kudo-Saito C, Grosenbach DW, Chakraborty M, Gulley JL, Arlen PM, Schlom J, Hodge JW: TRICOM vector based cancer vaccines. Curr Pharm Des. 2006, 12: 351-361.CrossRefPubMed
39.
go back to reference Mackensen A, Herbst B, Chen JL, Kohler G, Noppen C, Herr W, Spagnoli GC, Cerundolo V, Lindemann A: Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int J Cancer. 2000, 86: 385-392.CrossRefPubMed Mackensen A, Herbst B, Chen JL, Kohler G, Noppen C, Herr W, Spagnoli GC, Cerundolo V, Lindemann A: Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int J Cancer. 2000, 86: 385-392.CrossRefPubMed
40.
go back to reference Loveland BE, Zhao A, White S, Gan H, Hamilton K, Xing PX, Pietersz GA, Apostolopoulos V, Vaughan H, Karanikas V: Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Clin Cancer Res. 2006, 12: 869-877.CrossRefPubMed Loveland BE, Zhao A, White S, Gan H, Hamilton K, Xing PX, Pietersz GA, Apostolopoulos V, Vaughan H, Karanikas V: Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Clin Cancer Res. 2006, 12: 869-877.CrossRefPubMed
41.
go back to reference Mu LJ, Kyte JA, Kvalheim G, Aamdal S, Dueland S, Hauser M, Hammerstad H, Waehre H, Raabe N, Gaudernack G: Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients. Br J Cancer. 2005, 93: 749-756.PubMedCentralCrossRefPubMed Mu LJ, Kyte JA, Kvalheim G, Aamdal S, Dueland S, Hauser M, Hammerstad H, Waehre H, Raabe N, Gaudernack G: Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients. Br J Cancer. 2005, 93: 749-756.PubMedCentralCrossRefPubMed
42.
go back to reference Huang J, Khong HT, Dudley ME, El-Gamil M, Li YF, Rosenberg SA, Robbins PF: Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J Immunother. 2005, 28: 258-267.PubMedCentralCrossRefPubMed Huang J, Khong HT, Dudley ME, El-Gamil M, Li YF, Rosenberg SA, Robbins PF: Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J Immunother. 2005, 28: 258-267.PubMedCentralCrossRefPubMed
44.
go back to reference Prehn RT, Prehn LM: Immunostimulation of cancer versus immunosurveillance. Medicina (B Aires). 1996, 56 (Suppl 1): 65-73. Prehn RT, Prehn LM: Immunostimulation of cancer versus immunosurveillance. Medicina (B Aires). 1996, 56 (Suppl 1): 65-73.
45.
go back to reference Seliger B, Rongcun Y, Atkins D, Hammers S, Huber C, Storkel S, Kiessling R: HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes. Int J Cancer. 2000, 87: 349-359.CrossRefPubMed Seliger B, Rongcun Y, Atkins D, Hammers S, Huber C, Storkel S, Kiessling R: HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes. Int J Cancer. 2000, 87: 349-359.CrossRefPubMed
46.
go back to reference Kim B, Suvas S, Sarangi PP, Lee S, Reisfeld RA, Rouse BT: Vascular endothelial growth factor receptor 2-based DNA immunization delays development of herpetic stromal keratitis by antiangiogenic effects. J Immunol. 2006, 177: 4122-4131.CrossRefPubMed Kim B, Suvas S, Sarangi PP, Lee S, Reisfeld RA, Rouse BT: Vascular endothelial growth factor receptor 2-based DNA immunization delays development of herpetic stromal keratitis by antiangiogenic effects. J Immunol. 2006, 177: 4122-4131.CrossRefPubMed
47.
go back to reference Su JM, Wei YQ, Tian L, Zhao X, Yang L, He QM, Wang Y, Lu Y, Wu Y, Liu F: Active immunogene therapy of cancer with vaccine on the basis of chicken homologous matrix metalloproteinase-2. Cancer Res. 2003, 63: 600-607.PubMed Su JM, Wei YQ, Tian L, Zhao X, Yang L, He QM, Wang Y, Lu Y, Wu Y, Liu F: Active immunogene therapy of cancer with vaccine on the basis of chicken homologous matrix metalloproteinase-2. Cancer Res. 2003, 63: 600-607.PubMed
48.
go back to reference Godefroy E, Moreau-Aubry A, Diez E, Dreno B, Jotereau F, Guilloux Y: alpha v beta3-dependent cross-presentation of matrix metalloproteinase-2 by melanoma cells gives rise to a new tumor antigen. J Exp Med. 2005, 202: 61-72.PubMedCentralCrossRefPubMed Godefroy E, Moreau-Aubry A, Diez E, Dreno B, Jotereau F, Guilloux Y: alpha v beta3-dependent cross-presentation of matrix metalloproteinase-2 by melanoma cells gives rise to a new tumor antigen. J Exp Med. 2005, 202: 61-72.PubMedCentralCrossRefPubMed
49.
go back to reference Ishizaki H, Tsunoda T, Wada S, Yamauchi M, Shibuya M, Tahara H: Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1. Clin Cancer Res. 2006, 12: 5841-5849.CrossRefPubMed Ishizaki H, Tsunoda T, Wada S, Yamauchi M, Shibuya M, Tahara H: Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1. Clin Cancer Res. 2006, 12: 5841-5849.CrossRefPubMed
50.
go back to reference Jiao JG, Li YN, Wang H, Liu Q, Cao JX, Bai RZ, Huang FY: A plasmid DNA vaccine encoding the extracellular domain of porcine endoglin induces anti-tumour immune response against self-endoglin-related angiogenesis in two liver cancer models. Dig Liver Dis. 2006, 38: 578-587.CrossRefPubMed Jiao JG, Li YN, Wang H, Liu Q, Cao JX, Bai RZ, Huang FY: A plasmid DNA vaccine encoding the extracellular domain of porcine endoglin induces anti-tumour immune response against self-endoglin-related angiogenesis in two liver cancer models. Dig Liver Dis. 2006, 38: 578-587.CrossRefPubMed
51.
go back to reference Marleau AM, Greenwood JD, Wei Q, Singh B, Croy BA: Chimerism of murine fetal bone marrow by maternal cells occurs in late gestation and persists into adulthood. Lab Invest. 2003, 83: 673-681.CrossRefPubMed Marleau AM, Greenwood JD, Wei Q, Singh B, Croy BA: Chimerism of murine fetal bone marrow by maternal cells occurs in late gestation and persists into adulthood. Lab Invest. 2003, 83: 673-681.CrossRefPubMed
52.
go back to reference Jiang SP, Vacchio MS: Multiple mechanisms of peripheral T cell tolerance to the fetal "allograft". J Immunol. 1998, 160: 3086-3090.PubMed Jiang SP, Vacchio MS: Multiple mechanisms of peripheral T cell tolerance to the fetal "allograft". J Immunol. 1998, 160: 3086-3090.PubMed
53.
go back to reference Vacchio MS, Hodes RJ: Fetal expression of Fas ligand is necessary and sufficient for induction of CD8 T cell tolerance to the fetal antigen H-Y during pregnancy. J Immunol. 2005, 174: 4657-4661.CrossRefPubMed Vacchio MS, Hodes RJ: Fetal expression of Fas ligand is necessary and sufficient for induction of CD8 T cell tolerance to the fetal antigen H-Y during pregnancy. J Immunol. 2005, 174: 4657-4661.CrossRefPubMed
55.
go back to reference Sjogren HO, Hellstrom I, Bansal SC, Warner GA, Hellstrom KE: Elution of "blocking factors" from human tumors, capable of abrogating tumor-cell destruction by specifically immune lymphocytes. Int J Cancer. 1972, 9: 274-283.CrossRefPubMed Sjogren HO, Hellstrom I, Bansal SC, Warner GA, Hellstrom KE: Elution of "blocking factors" from human tumors, capable of abrogating tumor-cell destruction by specifically immune lymphocytes. Int J Cancer. 1972, 9: 274-283.CrossRefPubMed
56.
go back to reference Hellstrom I, Hellstrom KE, Sjogren HO: Serum mediated inhibition of cellular immunity to methylcholanthrene-induced murine sarcomas. Cell Immunol. 1970, 1: 18-30.CrossRefPubMed Hellstrom I, Hellstrom KE, Sjogren HO: Serum mediated inhibition of cellular immunity to methylcholanthrene-induced murine sarcomas. Cell Immunol. 1970, 1: 18-30.CrossRefPubMed
57.
go back to reference Sjogren HO, Hellstrom I, Bansal SC, Hellstrom KE: Suggestive evidence that the "blocking antibodies" of tumor-bearing individuals may be antigen – antibody complexes. Proc Natl Acad Sci USA. 1971, 68: 1372-1375.PubMedCentralCrossRefPubMed Sjogren HO, Hellstrom I, Bansal SC, Hellstrom KE: Suggestive evidence that the "blocking antibodies" of tumor-bearing individuals may be antigen – antibody complexes. Proc Natl Acad Sci USA. 1971, 68: 1372-1375.PubMedCentralCrossRefPubMed
58.
go back to reference Reichert TE, Strauss L, Wagner EM, Gooding W, Whiteside TL: Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res. 2002, 8: 3137-3145.PubMed Reichert TE, Strauss L, Wagner EM, Gooding W, Whiteside TL: Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res. 2002, 8: 3137-3145.PubMed
59.
go back to reference Agrawal S, Marquet J, Delfau-Larue MH, Copie-Bergman C, Jouault H, Reyes F, Bensussan A, Farcet JP: CD3 hyporesponsiveness and in vitro apoptosis are features of T cells from both malignant and nonmalignant secondary lymphoid organs. J Clin Invest. 1998, 102: 1715-1723.PubMedCentralCrossRefPubMed Agrawal S, Marquet J, Delfau-Larue MH, Copie-Bergman C, Jouault H, Reyes F, Bensussan A, Farcet JP: CD3 hyporesponsiveness and in vitro apoptosis are features of T cells from both malignant and nonmalignant secondary lymphoid organs. J Clin Invest. 1998, 102: 1715-1723.PubMedCentralCrossRefPubMed
60.
go back to reference Kim JW, Wieckowski E, Taylor DD, Reichert TE, Watkins S, Whiteside TL: Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin Cancer Res. 2005, 11: 1010-1020.PubMed Kim JW, Wieckowski E, Taylor DD, Reichert TE, Watkins S, Whiteside TL: Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin Cancer Res. 2005, 11: 1010-1020.PubMed
61.
go back to reference Poutsiaka DD, Schroder EW, Taylor DD, Levy EM, Black PH: Membrane vesicles shed by murine melanoma cells selectively inhibit the expression of Ia antigen by macrophages. J Immunol. 1985, 134: 138-144.PubMed Poutsiaka DD, Schroder EW, Taylor DD, Levy EM, Black PH: Membrane vesicles shed by murine melanoma cells selectively inhibit the expression of Ia antigen by macrophages. J Immunol. 1985, 134: 138-144.PubMed
62.
go back to reference Taylor DD, Lyons KS, Gercel-Taylor C: Shed membrane fragment-associated markers for endometrial and ovarian cancers. Gynecol Oncol. 2002, 84: 443-448.CrossRefPubMed Taylor DD, Lyons KS, Gercel-Taylor C: Shed membrane fragment-associated markers for endometrial and ovarian cancers. Gynecol Oncol. 2002, 84: 443-448.CrossRefPubMed
63.
go back to reference Taylor DD, Gercel-Taylor C, Lyons KS, Stanson J, Whiteside TL: T-cell apoptosis and suppression of T-cell receptor/CD3-zeta by Fas ligand-containing membrane vesicles shed from ovarian tumors. Clin Cancer Res. 2003, 9: 5113-5119.PubMed Taylor DD, Gercel-Taylor C, Lyons KS, Stanson J, Whiteside TL: T-cell apoptosis and suppression of T-cell receptor/CD3-zeta by Fas ligand-containing membrane vesicles shed from ovarian tumors. Clin Cancer Res. 2003, 9: 5113-5119.PubMed
64.
go back to reference Taylor DD, Black PH: Shedding of plasma membrane fragments. Neoplastic and developmental importance. Dev Biol (N Y 1985). 1986, 3: 33-57. Taylor DD, Black PH: Shedding of plasma membrane fragments. Neoplastic and developmental importance. Dev Biol (N Y 1985). 1986, 3: 33-57.
65.
go back to reference Lorentzen E, Conti E: The exosome and the proteasome: nano-compartments for degradation. Cell. 2006, 125: 651-654.CrossRefPubMed Lorentzen E, Conti E: The exosome and the proteasome: nano-compartments for degradation. Cell. 2006, 125: 651-654.CrossRefPubMed
66.
go back to reference Johnstone RM: Exosomes biological significance: A concise review. Blood Cells Mol Dis. 2006, 36: 315-321.CrossRefPubMed Johnstone RM: Exosomes biological significance: A concise review. Blood Cells Mol Dis. 2006, 36: 315-321.CrossRefPubMed
67.
68.
go back to reference Exosomes as an acellular mechanism to deliver allopeptides to recipient dendritic cells to promote the anti-donor T cell response. Transplantation. 82: 1019-1020. Exosomes as an acellular mechanism to deliver allopeptides to recipient dendritic cells to promote the anti-donor T cell response. Transplantation. 82: 1019-1020.
69.
go back to reference Chaput N, Schartz NE, Andre F, Taieb J, Novault S, Bonnaventure P, Aubert N, Bernard J, Lemonnier F, Merad M: Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. J Immunol. 2004, 172: 2137-2146.CrossRefPubMed Chaput N, Schartz NE, Andre F, Taieb J, Novault S, Bonnaventure P, Aubert N, Bernard J, Lemonnier F, Merad M: Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. J Immunol. 2004, 172: 2137-2146.CrossRefPubMed
70.
go back to reference Andre F, Chaput N, Schartz NE, Flament C, Aubert N, Bernard J, Lemonnier F, Raposo G, Escudier B, Hsu DH: Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J Immunol. 2004, 172: 2126-2136.CrossRefPubMed Andre F, Chaput N, Schartz NE, Flament C, Aubert N, Bernard J, Lemonnier F, Raposo G, Escudier B, Hsu DH: Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J Immunol. 2004, 172: 2126-2136.CrossRefPubMed
71.
go back to reference Abusamra AJ, Zhong Z, Zheng X, Li M, Ichim TE, Chin JL, Min WP: Tumor exosomes expressing Fas ligand mediate CD8+ T-cell apoptosis. Blood Cells Mol Dis. 2005, 35: 169-173.CrossRefPubMed Abusamra AJ, Zhong Z, Zheng X, Li M, Ichim TE, Chin JL, Min WP: Tumor exosomes expressing Fas ligand mediate CD8+ T-cell apoptosis. Blood Cells Mol Dis. 2005, 35: 169-173.CrossRefPubMed
72.
go back to reference Alonso R, Mazzeo C, Merida I, Izquierdo M: A new role of diacylglycerol kinase alpha on the secretion of lethal exosomes bearing Fas ligand during activation-induced cell death of T lymphocytes. Biochimie. 2006, 89 (2): 213-221.CrossRefPubMed Alonso R, Mazzeo C, Merida I, Izquierdo M: A new role of diacylglycerol kinase alpha on the secretion of lethal exosomes bearing Fas ligand during activation-induced cell death of T lymphocytes. Biochimie. 2006, 89 (2): 213-221.CrossRefPubMed
73.
go back to reference Kim SH, Lechman ER, Bianco N, Menon R, Keravala A, Nash J, Mi Z, Watkins SC, Gambotto A, Robbins PD: Exosomes derived from IL-10-treated dendritic cells can suppress inflammation and collagen-induced arthritis. J Immunol. 2005, 174: 6440-6448.CrossRefPubMed Kim SH, Lechman ER, Bianco N, Menon R, Keravala A, Nash J, Mi Z, Watkins SC, Gambotto A, Robbins PD: Exosomes derived from IL-10-treated dendritic cells can suppress inflammation and collagen-induced arthritis. J Immunol. 2005, 174: 6440-6448.CrossRefPubMed
74.
go back to reference Whiteside TL: Tumour-derived exosomes or microvesicles: another mechanism of tumour escape from the host immune system?. Br J Cancer. 2005, 92: 209-211.PubMedCentralCrossRefPubMed Whiteside TL: Tumour-derived exosomes or microvesicles: another mechanism of tumour escape from the host immune system?. Br J Cancer. 2005, 92: 209-211.PubMedCentralCrossRefPubMed
75.
go back to reference Frangsmyr L, Baranov V, Nagaeva O, Stendahl U, Kjellberg L, Mincheva-Nilsson L: Cytoplasmic microvesicular form of Fas ligand in human early placenta: switching the tissue immune privilege hypothesis from cellular to vesicular level. Mol Hum Reprod. 2005, 11: 35-41.CrossRefPubMed Frangsmyr L, Baranov V, Nagaeva O, Stendahl U, Kjellberg L, Mincheva-Nilsson L: Cytoplasmic microvesicular form of Fas ligand in human early placenta: switching the tissue immune privilege hypothesis from cellular to vesicular level. Mol Hum Reprod. 2005, 11: 35-41.CrossRefPubMed
76.
go back to reference Taylor DD, Akyol S, Gercel-Taylor C: Pregnancy-associated exosomes and their modulation of T cell signaling. J Immunol. 2006, 176: 1534-1542.CrossRefPubMed Taylor DD, Akyol S, Gercel-Taylor C: Pregnancy-associated exosomes and their modulation of T cell signaling. J Immunol. 2006, 176: 1534-1542.CrossRefPubMed
77.
go back to reference Mincheva-Nilsson L, Nagaeva O, Chen T, Stendahl U, Antsiferova J, Mogren I, Hernestal J, Baranov V: Placenta-Derived Soluble MHC Class I Chain-Related Molecules Down-Regulate NKG2D Receptor on Peripheral Blood Mononuclear Cells during Human Pregnancy: A Possible Novel Immune Escape Mechanism for Fetal Survival. J Immunol. 2006, 176: 3585-3592.CrossRefPubMed Mincheva-Nilsson L, Nagaeva O, Chen T, Stendahl U, Antsiferova J, Mogren I, Hernestal J, Baranov V: Placenta-Derived Soluble MHC Class I Chain-Related Molecules Down-Regulate NKG2D Receptor on Peripheral Blood Mononuclear Cells during Human Pregnancy: A Possible Novel Immune Escape Mechanism for Fetal Survival. J Immunol. 2006, 176: 3585-3592.CrossRefPubMed
78.
go back to reference Morelli AE: The immune regulatory effect of apoptotic cells and exosomes on dendritic cells: its impact on transplantation. Am J Transplant. 2006, 6: 254-261.CrossRefPubMed Morelli AE: The immune regulatory effect of apoptotic cells and exosomes on dendritic cells: its impact on transplantation. Am J Transplant. 2006, 6: 254-261.CrossRefPubMed
79.
go back to reference Peche H, Heslan M, Usal C, Amigorena S, Cuturi MC: Presentation of donor major histocompatibility complex antigens by bone marrow dendritic cell-derived exosomes modulates allograft rejection. Transplantation. 2003, 76: 1503-1510.CrossRefPubMed Peche H, Heslan M, Usal C, Amigorena S, Cuturi MC: Presentation of donor major histocompatibility complex antigens by bone marrow dendritic cell-derived exosomes modulates allograft rejection. Transplantation. 2003, 76: 1503-1510.CrossRefPubMed
80.
go back to reference Van Niel G, Mallegol J, Bevilacqua C, Candalh C, Brugiere S, Tomaskovic-Crook E, Heath JK, Cerf-Bensussan N, Heyman M: Intestinal epithelial exosomes carry MHC class II/peptides able to inform the immune system in mice. Gut. 2003, 52: 1690-1697.PubMedCentralCrossRefPubMed Van Niel G, Mallegol J, Bevilacqua C, Candalh C, Brugiere S, Tomaskovic-Crook E, Heath JK, Cerf-Bensussan N, Heyman M: Intestinal epithelial exosomes carry MHC class II/peptides able to inform the immune system in mice. Gut. 2003, 52: 1690-1697.PubMedCentralCrossRefPubMed
81.
82.
go back to reference Lentz MR: Continuous whole blood UltraPheresis procedure in patients with metastatic cancer. J Biol Response Mod. 1989, 8: 511-527.PubMed Lentz MR: Continuous whole blood UltraPheresis procedure in patients with metastatic cancer. J Biol Response Mod. 1989, 8: 511-527.PubMed
83.
go back to reference Tullis RH, Ambrus JA, Joyce JA: HIV affinity hemodialysis as a treatment for AIDS. Am Clin Lab. 2001, 20: 22-23.PubMed Tullis RH, Ambrus JA, Joyce JA: HIV affinity hemodialysis as a treatment for AIDS. Am Clin Lab. 2001, 20: 22-23.PubMed
84.
go back to reference Tullis RH, Duffin RP, Zech M, Ambrus JL: Affinity hemodialysis for antiviral therapy. I. Removal of HIV-1 from cell culture supernatants, plasma, and blood. Ther Apher. 2002, 6: 213-220.CrossRefPubMed Tullis RH, Duffin RP, Zech M, Ambrus JL: Affinity hemodialysis for antiviral therapy. I. Removal of HIV-1 from cell culture supernatants, plasma, and blood. Ther Apher. 2002, 6: 213-220.CrossRefPubMed
85.
go back to reference Tullis RH, Duffin RP, Zech M, Ambrus JL: Affinity hemodialysis for antiviral therapy. II. Removal of HIV-1 viral proteins from cell culture supernatants and whole blood. Blood Purif. 2003, 21: 58-63.CrossRefPubMed Tullis RH, Duffin RP, Zech M, Ambrus JL: Affinity hemodialysis for antiviral therapy. II. Removal of HIV-1 viral proteins from cell culture supernatants and whole blood. Blood Purif. 2003, 21: 58-63.CrossRefPubMed
86.
go back to reference Litynska A, Przybylo M, Pochec E, Hoja-Lukowicz D, Ciolczyk D, Laidler P, Gil D: Comparison of the lectin-binding pattern in different human melanoma cell lines. Melanoma Res. 2001, 11: 205-212.CrossRefPubMed Litynska A, Przybylo M, Pochec E, Hoja-Lukowicz D, Ciolczyk D, Laidler P, Gil D: Comparison of the lectin-binding pattern in different human melanoma cell lines. Melanoma Res. 2001, 11: 205-212.CrossRefPubMed
87.
go back to reference Schwarz RE, Wojciechowicz DC, Picon AI, Schwarz MA, Paty PB: Wheatgerm agglutinin-mediated toxicity in pancreatic cancer cells. Br J Cancer. 1999, 80: 1754-1762.PubMedCentralCrossRefPubMed Schwarz RE, Wojciechowicz DC, Picon AI, Schwarz MA, Paty PB: Wheatgerm agglutinin-mediated toxicity in pancreatic cancer cells. Br J Cancer. 1999, 80: 1754-1762.PubMedCentralCrossRefPubMed
88.
go back to reference Nakayama J, Katsuyama T, Ono K, Honda T, Akamatsu T, Hattori H: Large bowel carcinoma-specific antigens detected by the lectin, Griffonia simplicifolia agglutinin-II. Jpn J Cancer Res. 1985, 76: 1078-1084.PubMed Nakayama J, Katsuyama T, Ono K, Honda T, Akamatsu T, Hattori H: Large bowel carcinoma-specific antigens detected by the lectin, Griffonia simplicifolia agglutinin-II. Jpn J Cancer Res. 1985, 76: 1078-1084.PubMed
Metadata
Title
Exosomes as a tumor immune escape mechanism: possible therapeutic implications
Authors
Thomas E Ichim
Zhaohui Zhong
Shalesh Kaushal
Xiufen Zheng
Xiubao Ren
Xishan Hao
James A Joyce
Harold H Hanley
Neil H Riordan
James Koropatnick
Vladimir Bogin
Boris R Minev
Wei-Ping Min
Richard H Tullis
Publication date
01-12-2008
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2008
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-6-37

Other articles of this Issue 1/2008

Journal of Translational Medicine 1/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.